Skip to content
Screener

Ultragenyx Pharmaceutical RARE Liabilities For Sales Of Future Royalties Current

Liabilities For Sales Of Future Royalties Current at other companies

Mannkind logo
MannkindMNKD
$14.29M+7.1%
Mannkind logo
MannkindMNKD
$14.29M+7.1%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$305.04M+22.9%
Mannkind logo
MannkindMNKD
$133.55M-2.7%
Mannkind logo
MannkindMNKD
$133.55M-2.7%
Mannkind logo
MannkindMNKD
$470K-32.2%

Other financials

Income statement

See full
Revenue$214.0M+28.1%
Operating income-$75.0M+30.6%
Net income-$92.0M+20.0%
EPS (diluted)-$0.90+23.1%

Balance sheet

See full
Cash & equivalents$125.0M-29.0%
Total debt$36.0M-10.8%
Total equity-$291.0M-293%
Total assets$1.3B-3.2%

Cash flow

See full
Operating cash flow-$97.0M+11.0%
CapEx$1.0M-66.7%
Free cash flow-$98.0M+12.5%

Valuation

See full
Market cap$2.55B-5.8%
P/S3.6×-0.9×

Profitability

See full
Gross margin97.2%
Operating margin-73.6%-7.3pp
Net margin-81.7%-4.9pp
FCF margin-68.2%-1.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×
Current ratio1.7×-0.7×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept rare:LiabilitiesForSalesOfFutureRoyaltiesCurrent.

The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.

Filed
Aug 4, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333233
Line itemJune 30, 2026December 31, 2025
Current liabilities:
Accounts payable$39$31
Accrued liabilities221265
Liabilities for sales of future royalties7669
Other liabilities1519
Total current liabilities351384
Deferred tax liabilities3030
Liabilities for sales of future royalties1,1261,147

Item 1. Financial Statements

FAQ

What is Ultragenyx Pharmaceutical's liabilities for sales of future royalties current?
Ultragenyx Pharmaceutical (RARE) reported liabilities for sales of future royalties current of $76M in Q2 2026.
How has Ultragenyx Pharmaceutical's liabilities for sales of future royalties current changed year-over-year?
Ultragenyx Pharmaceutical's liabilities for sales of future royalties current increased by 19.0% year-over-year, from $63.86M to $76M.
What does liabilities for sales of future royalties current mean?
This represents the portion of obligations arising from the monetization of future royalty streams that is due within the next twelve months. It reflects the company's commitment to pay out future revenue generated from specific products or intellectual property to third-party investors. Managing this liability is critical for assessing short-term cash flow obligations and the impact of non-dilutive financing arrangements on near-term liquidity.

Ask your AI about Ultragenyx Pharmaceutical's liabilities for sales of future royalties current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude